Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease
Abstract Pompe disease (PD) is a progressive myopathy caused by the aberrant accumulation of glycogen in skeletal and cardiac muscle resulting from the deficiency of the enzyme acid alpha‐glucosidase (GAA). Administration of recombinant human GAA as enzyme replacement therapy (ERT) works well in all...
Saved in:
| Main Authors: | Lan Weiss, Michele Carrer, Alyaa Shmara, Angela Martin, Hong Yin, Pallabi Pal, Cheng Cheng, Lac Ta, Victoria Boock, Yasamin Fazeli, Mindy Chang, Marvin Paguio, Jonathan Lee, Howard Yu, John Weiss, Tamar R Grossman, Nina Raben, Paymaan Jafar‐Nejad, Virginia Kimonis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70314 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical manifestations in Egyptian Pompe disease patients: Molecular variability and enzyme replacement therapy (ERT) outcomes
by: Mohamed Abdelghafar Hussein, et al.
Published: (2025-01-01) -
Late-onset Pompe disease: preliminary results of enzyme replacement therapy
by: L. P. Smertina, et al.
Published: (2019-07-01) -
Late-onset Pompe disease with phenotype of the limb-girdle muscular dystrophy
by: S. A. Kurbatov, et al.
Published: (2015-09-01) -
Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease
by: Juan Clinton Llerena Junior, et al.
Published: (2015-01-01) -
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01)